Add to favorites

#Industry News

Brief Summary of Neoadjuvant Immunotherapy Research Progress in NSCLC

As the most common cancer with the highest incidence and mortality rates worldwide, lung cancer has attracted significant attention from people worldwide.

Neoadjuvant immunotherapy for lung cancer mainly refers to the use of immune checkpoint inhibitors (ICIs) to eliminate the immune suppression of tumor cells on T cells by blocking immune checkpoint molecules such as PD-1/PD-L1/CTLA-4, and thereby reactivating T cells to clear tumor cells [2]. Currently, clinical research on neoadjuvant immunotherapy for Non-small cell lung cancer (NSCLC) has become a hot topic, and clinical schemes include PD-1 inhibitor monotherapy, PD-L1 inhibitor monotherapy, immunotherapy combined with chemotherapy, and ICI dual therapy. The following will introduce each treatment scheme.

Brief Summary of Neoadjuvant Immunotherapy Research Progress in NSCLC

Details

  • Xiamen, Fujian, China
  • SPACEGEN